Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

An agonist of the MscL channel affects multiple bacterial species and increases membrane permeability and potency of common antibiotics.

Wray R, Herrera N, Iscla I, Wang J, Blount P.

Mol Microbiol. 2019 Sep;112(3):896-905. doi: 10.1111/mmi.14325. Epub 2019 Jun 8.

2.

Interaction of the Mechanosensitive Channel, MscS, with the Membrane Bilayer through Lipid Intercalation into Grooves and Pockets.

Rasmussen T, Rasmussen A, Yang L, Kaul C, Black S, Galbiati H, Conway SJ, Miller S, Blount P, Booth IR.

J Mol Biol. 2019 Aug 9;431(17):3339-3352. doi: 10.1016/j.jmb.2019.05.043. Epub 2019 Jun 4.

3.

Human mutations highlight an intersubunit cation-π bond that stabilizes the closed but not open or inactivated states of TRPV channels.

Teng J, Anishkin A, Kung C, Blount P.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9410-9416. doi: 10.1073/pnas.1820673116. Epub 2019 Apr 22.

PMID:
31010928
4.

Effects of Low Intensity Focused Ultrasound on Liposomes Containing Channel proteins.

Babakhanian M, Yang L, Nowroozi B, Saddik G, Boodaghians L, Blount P, Grundfest W.

Sci Rep. 2018 Nov 22;8(1):17250. doi: 10.1038/s41598-018-35486-1.

5.

Novel compounds that specifically bind and modulate MscL: insights into channel gating mechanisms.

Wray R, Iscla I, Kovacs Z, Wang J, Blount P.

FASEB J. 2019 Mar;33(3):3180-3189. doi: 10.1096/fj.201801628R. Epub 2018 Oct 25.

PMID:
30359098
6.

Engineering a pH-Sensitive Liposomal MRI Agent by Modification of a Bacterial Channel.

Yang LM, Zheng H, Ratnakar JS, Adebesin BY, Do QN, Kovacs Z, Blount P.

Small. 2018 May;14(19):e1704256. doi: 10.1002/smll.201704256. Epub 2018 Apr 11.

7.

Dihydrostreptomycin Directly Binds to, Modulates, and Passes through the MscL Channel Pore.

Wray R, Iscla I, Gao Y, Li H, Wang J, Blount P.

PLoS Biol. 2016 Jun 9;14(6):e1002473. doi: 10.1371/journal.pbio.1002473. eCollection 2016 Jun.

8.

Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus.

Hardikar S, Song X, Risques RA, Montine TJ, Duggan C, Blount PL, Reid BJ, Anderson GL, Kratz M, White E, Vaughan TL.

BMC Obes. 2015 Sep 10;2:32. doi: 10.1186/s40608-015-0063-3. eCollection 2015.

9.

Scanning MscL Channels with Targeted Post-Translational Modifications for Functional Alterations.

Iscla I, Wray R, Eaton C, Blount P.

PLoS One. 2015 Sep 14;10(9):e0137994. doi: 10.1371/journal.pone.0137994. eCollection 2015.

10.

Mutations in a Conserved Domain of E. coli MscS to the Most Conserved Superfamily Residue Leads to Kinetic Changes.

Malcolm HR, Blount P.

PLoS One. 2015 Sep 4;10(9):e0136756. doi: 10.1371/journal.pone.0136756. eCollection 2015.

11.

High Goblet Cell Count Is Inversely Associated with Ploidy Abnormalities and Risk of Adenocarcinoma in Barrett's Esophagus.

Srivastava A, Golden KL, Sanchez CA, Liu K, Fong PY, Li X, Cowan DS, Rabinovitch PS, Reid BJ, Blount PL, Odze RD.

PLoS One. 2015 Jul 31;10(7):e0133403. doi: 10.1371/journal.pone.0133403. eCollection 2015.

12.

Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.

Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, Maley CC, Self SG, Vaughan TL, Reid BJ, Blount PL.

Cancer Prev Res (Phila). 2015 Sep;8(9):845-56. doi: 10.1158/1940-6207.CAPR-15-0130. Epub 2015 Jun 30.

13.

Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett's Esophagus Cohort.

Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, Li X, Vaughan TL, Matsen FA, Reid BJ, Salama NR.

PLoS One. 2015 Jun 15;10(6):e0129055. doi: 10.1371/journal.pone.0129055. eCollection 2015.

14.

A new antibiotic with potent activity targets MscL.

Iscla I, Wray R, Blount P, Larkins-Ford J, Conery AL, Ausubel FM, Ramu S, Kavanagh A, Huang JX, Blaskovich MA, Cooper MA, Obregon-Henao A, Orme I, Tjandra ES, Stroeher UH, Brown MH, Macardle C, van Holst N, Ling Tong C, Slattery AD, Gibson CT, Raston CL, Boulos RA.

J Antibiot (Tokyo). 2015 Jul;68(7):453-62. doi: 10.1038/ja.2015.4. Epub 2015 Feb 4.

15.

The mechanosensitive channel of small conductance (MscS) functions as a Jack-in-the box.

Malcolm HR, Blount P, Maurer JA.

Biochim Biophys Acta. 2015 Jan;1848(1 Pt A):159-66. doi: 10.1016/j.bbamem.2014.10.022. Epub 2014 Oct 23.

16.

Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.

Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL.

Carcinogenesis. 2014 Dec;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3.

17.

Electrostatics at the membrane define MscL channel mechanosensitivity and kinetics.

Zhong D, Blount P.

FASEB J. 2014 Dec;28(12):5234-41. doi: 10.1096/fj.14-259309. Epub 2014 Sep 15.

18.

Streptomycin potency is dependent on MscL channel expression.

Iscla I, Wray R, Wei S, Posner B, Blount P.

Nat Commun. 2014 Sep 10;5:4891. doi: 10.1038/ncomms5891.

19.

Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.

Hardikar S, Onstad L, Song X, Wilson AM, Montine TJ, Kratz M, Anderson GL, Blount PL, Reid BJ, White E, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393-403. doi: 10.1158/1055-9965.EPI-14-0384. Epub 2014 Aug 8.

20.

Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage.

Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, Vaughan TL, White E.

Cancer Causes Control. 2014 Aug;25(8):969-76. doi: 10.1007/s10552-014-0396-0. Epub 2014 May 17.

21.

Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention.

Li X, Blount PL, Reid BJ, Vaughan TL.

BMC Med Inform Decis Mak. 2014 Mar 6;14:15. doi: 10.1186/1472-6947-14-15.

22.

Dynamics of protein-protein interactions at the MscL periplasmic-lipid interface.

Zhong D, Yang LM, Blount P.

Biophys J. 2014 Jan 21;106(2):375-81. doi: 10.1016/j.bpj.2013.12.006.

23.

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.

Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Sather CL, Kostadinov RL, Odze RD, Kuhner MK, Maley CC, Self SG, Vaughan TL, Blount PL, Reid BJ.

Cancer Prev Res (Phila). 2014 Jan;7(1):114-27. doi: 10.1158/1940-6207.CAPR-13-0289. Epub 2013 Nov 19.

24.

Phosphatidylinositol is crucial for the mechanosensitivity of Mycobacterium tuberculosis MscL.

Zhong D, Blount P.

Biochemistry. 2013 Aug 13;52(32):5415-20. doi: 10.1021/bi400790j. Epub 2013 Aug 1.

25.

NSAIDs modulate clonal evolution in Barrett's esophagus.

Kostadinov RL, Kuhner MK, Li X, Sanchez CA, Galipeau PC, Paulson TG, Sather CL, Srivastava A, Odze RD, Blount PL, Vaughan TL, Reid BJ, Maley CC.

PLoS Genet. 2013 Jun;9(6):e1003553. doi: 10.1371/journal.pgen.1003553. Epub 2013 Jun 13.

26.

Improving the Design of a MscL-Based Triggered Nanovalve.

Iscla I, Eaton C, Parker J, Wray R, Kovács Z, Blount P.

Biosensors (Basel). 2013;3(1):171-84. doi: 10.3390/bios3010171.

27.

Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.

Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ, Vaughan TL.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):934-43. doi: 10.1016/j.cgh.2013.02.017. Epub 2013 Mar 1.

28.

Chimeras reveal a single lipid-interface residue that controls MscL channel kinetics as well as mechanosensitivity.

Yang LM, Zhong D, Blount P.

Cell Rep. 2013 Feb 21;3(2):520-7. doi: 10.1016/j.celrep.2013.01.018. Epub 2013 Feb 14.

29.

The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus.

Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL.

PLoS One. 2013;8(1):e52192. doi: 10.1371/journal.pone.0052192. Epub 2013 Jan 3.

30.

Structure and molecular mechanism of an anion-selective mechanosensitive channel of small conductance.

Zhang X, Wang J, Feng Y, Ge J, Li W, Sun W, Iscla I, Yu J, Blount P, Li Y, Yang M.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18180-5. doi: 10.1073/pnas.1207977109. Epub 2012 Oct 16.

31.

The dynamics of protein-protein interactions between domains of MscL at the cytoplasmic-lipid interface.

Iscla I, Wray R, Blount P.

Channels (Austin). 2012 Jul-Aug;6(4):255-61. doi: 10.4161/chan.20756. Epub 2012 Jul 1.

32.

Sensing and responding to membrane tension: the bacterial MscL channel as a model system.

Iscla I, Blount P.

Biophys J. 2012 Jul 18;103(2):169-74. doi: 10.1016/j.bpj.2012.06.021. Epub 2012 Jul 17. Review.

33.

Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.

Takata Y, Kristal AR, Santella RM, King IB, Duggan DJ, Lampe JW, Rayman MP, Blount PL, Reid BJ, Vaughan TL, Peters U.

PLoS One. 2012;7(6):e38612. doi: 10.1371/journal.pone.0038612. Epub 2012 Jun 8.

34.

The MscS and MscL families of mechanosensitive channels act as microbial emergency release valves.

Booth IR, Blount P.

J Bacteriol. 2012 Sep;194(18):4802-9. doi: 10.1128/JB.00576-12. Epub 2012 Jun 8. Review.

35.

Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus.

Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):456-61. doi: 10.1158/1055-9965.EPI-11-1014. Epub 2012 Jan 12.

36.

Three routes to modulate the pore size of the MscL channel/nanovalve.

Yang LM, Wray R, Parker J, Wilson D, Duran RS, Blount P.

ACS Nano. 2012 Feb 28;6(2):1134-41. doi: 10.1021/nn203703j. Epub 2012 Jan 6.

37.

The oligomeric state of the truncated mechanosensitive channel of large conductance shows no variance in vivo.

Iscla I, Wray R, Blount P.

Protein Sci. 2011 Sep;20(9):1638-42. doi: 10.1002/pro.686. Epub 2011 Jul 19.

38.

Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view.

Li X, Blount PL, Vaughan TL, Reid BJ.

PLoS Comput Biol. 2011 Feb;7(2):e1001087. doi: 10.1371/journal.pcbi.1001087. Epub 2011 Feb 24.

39.

S. aureus MscL is a pentamer in vivo but of variable stoichiometries in vitro: implications for detergent-solubilized membrane proteins.

Dorwart MR, Wray R, Brautigam CA, Jiang Y, Blount P.

PLoS Biol. 2010 Dec 7;8(12):e1000555. doi: 10.1371/journal.pbio.1000555.

40.

An in vivo screen reveals protein-lipid interactions crucial for gating a mechanosensitive channel.

Iscla I, Wray R, Blount P.

FASEB J. 2011 Feb;25(2):694-702. doi: 10.1096/fj.10-170878. Epub 2010 Nov 10.

41.

A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.

Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, Maley CC.

Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97. doi: 10.1158/1940-6207.CAPR-10-0108. Epub 2010 Oct 12.

42.

Manipulating the permeation of charged compounds through the MscL nanovalve.

Yang LM, Blount P.

FASEB J. 2011 Jan;25(1):428-34. doi: 10.1096/fj.10-170076. Epub 2010 Oct 7.

43.

Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.

Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL, Odze RD, Vaughan TL, Blount PL, Reid BJ.

Clin Cancer Res. 2009 May 15;15(10):3305-14. doi: 10.1158/1078-0432.CCR-08-2494. Epub 2009 May 5.

44.

Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus.

Hahn HP, Blount PL, Ayub K, Das KM, Souza R, Spechler S, Odze RD.

Am J Surg Pathol. 2009 Jul;33(7):1006-15. doi: 10.1097/PAS.0b013e31819f57e9.

45.

An open-pore structure of the mechanosensitive channel MscL derived by determining transmembrane domain interactions upon gating.

Li Y, Wray R, Eaton C, Blount P.

FASEB J. 2009 Jul;23(7):2197-204. doi: 10.1096/fj.09-129296. Epub 2009 Mar 4.

46.

Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study.

Rucker-Schmidt RL, Sanchez CA, Blount PL, Ayub K, Li X, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2009 Jun;33(6):886-93. doi: 10.1097/PAS.0b013e318198a1d4.

47.

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.

Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, Peiffer DA, Pokholok D, Gunderson KL, Reid BJ.

Cancer Prev Res (Phila). 2008 Nov;1(6):413-23. doi: 10.1158/1940-6207.CAPR-08-0121.

48.

p16 mutation spectrum in the premalignant condition Barrett's esophagus.

Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL, Sanchez CA, Odze RD, Reid BJ.

PLoS One. 2008;3(11):e3809. doi: 10.1371/journal.pone.0003809. Epub 2008 Nov 27.

49.

Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.

Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS, Ayub K, Odze RD, Rabinovitch PS, Reid BJ.

Clin Cancer Res. 2008 Nov 1;14(21):6988-95. doi: 10.1158/1078-0432.CCR-07-5063.

50.

River tree rope swing injuries.

Sorey WH, Cassidy LD, Crout J, Blount P.

South Med J. 2008 Jul;101(7):699-702. doi: 10.1097/SMJ.0b013e31817a7eb0.

PMID:
18580723

Supplemental Content

Loading ...
Support Center